 |
 |
|
|
|
| Sorafenib tosylate |
 |
| N-[4-Chloro-3-(trifluoromethyl)phenyl]-({4-[2-(N-methyl-carbamoyl)(4-pyridyloxy)]phenyl}-amino)carboxamide tosylate |
 |
| [475207-59-1] |
 |
| Use: Sorafenib is the first oral multi-kinase inhibitor that targets serine/ threonine and receptor tyrosine kinases in both the tumor cell and the tumor vasculature, said Ronald Bukowski, M.D., director of experimental therapeutics at the Cleveland Clinic Taussig Cancer Center in Ohio. In preclinical models, sorafenib targeted members of two classes of kinases, including RAF kinase, VEGFR-2, VEGFR-3, PDGFR-B, KIT, and FLT-3. These kinases are known to be involved in both tumor cell proliferation and tumor angiogenesis. |
 |
Appearance: Off-white crystalline powder.
|
|
|
|
|
|
